The Absence of Immunoreactivity for Tissue Inhibitor of Metalloproteinase-1 (TIMP-1), but Not for TIMP-2, Protein Is Associated with a Favorable Prognosis in Aggressive Breast Carcinoma
Authors:
- Anne Talvensaari-MattilaATAnne Talvensaari-Mattila
- Paavo PääkköPPPaavo Pääkkö
- Taina Turpeenniemi-HujanenTTTaina Turpeenniemi-Hujanen
- 1 July 2005
- journal article
- Published by S. Karger AG in Oncology
- Vol. 68 (2-3) , 196-203
Abstract
Objectives: High tumor grade and lymph node positivity are associated with poor prognosis in breast carcinoma. Prognostic markers are used to define which patient groups benefit from different treatment modalities, some of which are potentially very toxic. Matrix metalloproteinases (MMPs) degrade the extracellular matrix, and type IV collagenases MMP-2 and -9 have been linked to invasive behavior of several malignancies. Tissue inhibitors of metalloproteinases (TIMPs) -1 and -2 inhibit their activity and are therefore considered to have an inhibitory effect on tumor progression. The role of TIMPs in progression of breast carcinoma is, however, still poorly known. Here the effect of TIMP-1 and -2 on survival was examined in lymph node-positive breast carcinoma patients. Methods: TIMP-1 or -2 was evaluated with avidin-biotin immunohistochemical staining from paraffin-embedded sections of primary breast carcinoma of 132 cases. Results: Positive staining for TIMP-1 and -2 was observed in 81 and 84% of the tumors respectively. TIMP-1 correlated to the grade of the tumor (p = 0.047). Absence of TIMP-1 protein correlated with favorable disease-specific survival of the patients with high-grade tumors. After 10 years of follow-up as high as 88% of patients with a grade 2–3, but TIMP-1-negative tumor were alive, when only 61% of the TIMP-1-positive cases in this group survived by that time (p = 0.03). Conclusion: Our results suggest that lack of TIMP-1 protein expression is associated with a favorable prognosis in patients with node-positive high-grade breast carcinoma.Keywords
This publication has 21 references indexed in Scilit:
- Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinomaBritish Journal of Cancer, 2003
- Matrix Metalloproteinase-2 (MMP-2) in T1–2N0 breast carcinomaBreast Cancer Research and Treatment, 2003
- Matrix Metalloproteinases: Biologic Activity and Clinical ImplicationsJournal of Clinical Oncology, 2000
- Matrix metalloproteinase-2 immunoreactive proteinCancer, 1998
- Changing views of the role of matrix metalloproteinases in metastasisJNCI: Journal of the National Cancer Institute, 1997
- Type IV collagenases in invasive tumorsBreast Cancer Research and Treatment, 1993
- Tissue inhibitor of metalloproteinases (TIMP, aka EPA): Structure, control of expression and biological functionsPharmacology & Therapeutics, 1993
- Tissue inhibitor of metalloproteinase‐2 (TIMP‐2) has erythroid‐potentiating activityFEBS Letters, 1992
- Tissue inhibitor of metalloproteinases from human bone marrow stromal cell line KM 102 has erythroid‐potentiating activity, suggesting its possibly bifunctional role in the hematopoietic microenvironmentFEBS Letters, 1990
- Histological Grading and Prognosis in Breast CancerBritish Journal of Cancer, 1957